SAT0109 Relationship Between Early Disease Activity Status and Structural and Functional Changes In Mtx-NaÏVe Patients with Early RA Treated with Abatacept Plus Mtx Versus Mtx Alone in the Agree Trial. (23rd January 2014)

• Record Type: Journal Article
• Authors: Smolen, J. S.; Yazici, Y.; Wollenhaupt, J.; Durez, P.; Gomez-Reino, J.; Grassi, W.; Le Bars, M.; Gaillez, C.; Poncet, C.; Westhovens, R.
• Is Part Of: Annals of the rheumatic diseases. Volume 72:Supplement 3(2013)
• Page Start: A617
• Page End: A617
• Publication Date: 2014-01-23
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2013-eular.1835
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: In patients (pts) with early RA receiving MTX, remission improves long-term functional and structural outcomes. However, dissociation between clinical and structural outcomes has been reported with biologic treatment of early RA in pts with poor prognostic factors. Objectives: To explore changes in structural and functional outcomes at Month(M)12 according to disease activity at M3 in the AGREE trial. Methods: In AGREE, pts with early RA and poor prognostic factors were randomized to ABA+MTX or MTX alone for 12 months. 1 This was a post hoc, as-observed analysis of mean (95% CI) change from baseline (BL) to M12 in Genant-modified Sharp TS and HAQ-DI score according to DAS28, SDAI and CDAI status at M3, for pts with efficacy data available at BL, M6 and M12. Results: Mean BL scores for disease activity, structural and functional status were similar between original treatment groups. 1 Change from BL to M12 in X-ray TS and HAQ-DI scores according to M3 disease activity status (low [LDA]; moderate [MDA]; high [HDA]) are shown. Conclusions: This post hoc analysis indicated numerical trends that remission or LDA at M3 may be associated with less X-ray progression and greater functional improvements from BL to M12 than moderate/high disease at M3; somewhat less progression of X-ray score with ABA+MTX vs MTX alone was also observed in pts with moderate/high disease at M3, suggesting a protective effect of ABA on joint damage even in these pts; ABA+MTX conferred greater reductions in HAQ-DI score vs MTX alone, regardless of disease activity. References: Westhovens R, et al. Ann Rheum Dis 2009;68 :1870–7 Disclosure of Interest: J. Smolen Grant/research support from: Abbott, Bristol-Myers Squibb, Hoffmann-La Roche, Schering-Plough, UCB, Pfizer, Consultant for: Abbott, Amgen, AstraZeneca, Bristol-Myers Squibb, Centocor, Eli-Lilly, Merck, Novo Nordisk, Roche, sanofi-aventis, UCB, Y. Yazici Grant/research support from: Centocor, Bristol-Myers Squibb, Genentech, Consultant for: Bristol-Myers Squibb, Celgene, Genentech, Horizon, UCB, Roche, Pfizer, Speakers bureau: Bristol-Myers Squibb, J. Wollenhaupt Consultant for: Bristol-Myers Squibb, Chugai, Roche, Speakers bureau: Chugai, Roche, P. Durez Speakers bureau: Bristol-Myers Squibb, J. Gomez-Reino Grant/research support from: Roche, Schering-Plough, Wyeth Pharmaceuticals, UCB, Consultant for: Hoffmann-La Roche, Roche, Schering-Plough, UCB, Pfizer, Bristol-Myers Squibb, Speakers bureau: Bristol-Myers Squibb, Roche, UCB, MSD, Pfizer, Abbott, W. Grassi Grant/research support from: Abbott, Bristol-Myers Squibb, Esaote, General Electric, Menarini, Merck Sharp & Dohme, Pfizer, Roche, Schering-Plough, UCB, Consultant for: Abbott, Bristol-Myers Squibb, Esaote, General Electric, Menarini, Merck Sharp & Dohme, Pfizer, Roche, Schering-Plough, UCB, M. Le Bars Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, C. Gaillez Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, C. Poncet Consultant for: Bristol-Myers Squibb, R. Westhovens Grant/research support from: Roche, UCB, Consultant for: Bristol-Myers Squibb, Galapagos, Janssen, Speakers bureau: Bristol-Myers Squibb